CA2456177A1 - Erythropoietine et traitement de combinaison alpha anti-facteur de necrose des tumeurs - Google Patents

Erythropoietine et traitement de combinaison alpha anti-facteur de necrose des tumeurs Download PDF

Info

Publication number
CA2456177A1
CA2456177A1 CA002456177A CA2456177A CA2456177A1 CA 2456177 A1 CA2456177 A1 CA 2456177A1 CA 002456177 A CA002456177 A CA 002456177A CA 2456177 A CA2456177 A CA 2456177A CA 2456177 A1 CA2456177 A1 CA 2456177A1
Authority
CA
Canada
Prior art keywords
tnf
alpha
epo
study
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002456177A
Other languages
English (en)
Inventor
Loretta Itri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2456177A1 publication Critical patent/CA2456177A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé permettant de traiter des sujets anémiques et non anémiques présentant des tumeurs malignes par une combinaison d'érythropoïétine (EPO) et d'un composé anti-facteur de nécrose des tumeurs, de sorte à réduire le besoin de transfusion et à augmenter le taux d'hémoglobine. L'invention concerne également un procédé permettant de traiter des sujets anémiques et non anémiques présentant des tumeurs malignes par une combinaison d'EPO et d'un composé anti-facteur de nécrose des tumeurs, de sorte à empêcher ou à traiter l'anémie de manière efficace pendant un régime chimiothérapique. L'invention concerne encore un procédé permettant de traiter des sujets anémiques ou non anémiques présentant des tumeurs malignes par une combinaison d'EPO et d'un composé anti-facteur de nécrose des tumeurs, de sorte que les patients ont une meilleure qualité de vie, que leurs symptômes de fatigue sont atténués et que leurs performances physiques et leur bien-être sont améliorés.
CA002456177A 2001-08-02 2001-08-02 Erythropoietine et traitement de combinaison alpha anti-facteur de necrose des tumeurs Abandoned CA2456177A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/024384 WO2003012432A1 (fr) 2001-08-02 2001-08-02 Erythropoietine et traitement de combinaison alpha anti-facteur de necrose des tumeurs

Publications (1)

Publication Number Publication Date
CA2456177A1 true CA2456177A1 (fr) 2003-02-13

Family

ID=21742749

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002456177A Abandoned CA2456177A1 (fr) 2001-08-02 2001-08-02 Erythropoietine et traitement de combinaison alpha anti-facteur de necrose des tumeurs

Country Status (4)

Country Link
EP (1) EP1423693A4 (fr)
JP (1) JP2004537569A (fr)
CA (1) CA2456177A1 (fr)
WO (1) WO2003012432A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004296765B2 (en) * 2003-12-02 2011-03-24 Celgene Corporation Methods and compositions for the treatment and management of hemoglobinopathy and anemia
WO2007139150A1 (fr) * 2006-05-30 2007-12-06 The University Of Tokushima AGENT ANTI-VIRUS DE LA GRIPPE COMPRENANT L'INHIBITEUR DU TNF-α
GR1005808B (el) * 2006-11-27 2008-02-06 Bionature E.A. Limited Επιταση της δρασεως της ερυθροποιητινης με αγωνιστες των μεμβρανικων στεροειδων υποδοχεων

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1466680A (zh) * 2000-08-02 2004-01-07 ����-������ҩƷ��˾ 给予促红细胞生成素改善抗病毒及抗肿瘤化疗
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra

Also Published As

Publication number Publication date
WO2003012432A1 (fr) 2003-02-13
JP2004537569A (ja) 2004-12-16
EP1423693A1 (fr) 2004-06-02
EP1423693A4 (fr) 2006-06-07

Similar Documents

Publication Publication Date Title
MXPA06014421A (es) Uso de inhibidores de vegf para el tratamiento de cancer humano.
CA2418531C (fr) Methodes therapeutiques de traitement de sujet avec une erytrhopoietine recombinee presentant une activite elevee et peu d'effets secondaires
JP5737826B2 (ja) Ｖｅｇｆの阻害による貧血の処置
WO2000067769A1 (fr) Ameliorations de la survie des patients souffrant du cancer traites avec de l'erythropoietine et des agents antitumoraux
RU2225221C2 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ Эритропоэтина
KR100478573B1 (ko) 류마티스 질환 치료용 약학 조합제제 제조를 위한에리트로포이에틴과 철 제제의 용도
Palmour et al. Characterization of a peptide from the serum of psychotic patients
Hellström et al. Treatment of myelodysplastic syndromes with recombinant human erythropoietin
KR20030043924A (ko) 에리트로포이에틴 투여에 의한 개선된 항-바이러스 및항-종양 화학 요법
Morreale et al. Clinical and economic comparison of epoetin alfa and darbepoetin alfa
Kuan et al. A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization
EP3868403A1 (fr) Protéine de fusion taci-fc et son utilisation
EP3845550A1 (fr) Composition pour l'accélération de la prolifération cellulaire comprenant un peptide dérivé de l'érythropoïétine
US20120082642A1 (en) Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors
WO2003013568A1 (fr) Therapie par modulation de cytokines
CA2456177A1 (fr) Erythropoietine et traitement de combinaison alpha anti-facteur de necrose des tumeurs
KR19990066997A (ko) 조혈성 간세포의 이동 방법
Geller et al. Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy‐induced diarrhea in bone marrow transplant and leukemia patients
EP4292603A1 (fr) Procédé de traitement d'une néphropathie à iga avec une protéine de fusion taci-fc
Ghio et al. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes
Tasaki et al. Iron and erythropoietin measurement in autologous blood donors with anemia: implications for management
Hudson et al. Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease
Vilan et al. Pure red cell aplasia: successful treatment with cyclophosphamide
Atkinson et al. Management of Anemia in Children Receiving Chronic Dialysis
Nayak et al. Novel Approaches in Erythropoietin: A Review

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead